Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (101-110 of 187) with videos related to

Pageof 19
Sort By:
Thrombosis and Haemostasis|December 5, 2014
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trialJames D Douketis, Jeff S Healey, Martina Brueckmann, et al.
Circulation|July 31, 2015
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and OutcomesWobo Bekwelem, Stuart J Connolly, Jonathan L Halperin, et al.
Thrombosis Research|February 27, 2016
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trialJames D Douketis, Jeff S Healey, Martina Brueckmann, et al.
Circulation|January 5, 2011
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversionRangadham Nagarakanti, Michael D Ezekowitz, Jonas Oldgren, et al.
Journal of the American Heart Association|January 18, 2019
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY TrialZiad Hijazi, Paolo Verdecchia, Jonas Oldgren, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Lancet (London, England)|August 31, 2010
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLars Wallentin, Salim Yusuf, Michael D Ezekowitz, et al.
Journal of the American Heart Association|December 9, 2020
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial FibrillationZiad Hijazi, Lars Wallentin, Johan Lindbäck, et al.
Cardiovascular Research|August 6, 2021
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillationTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Pageof 19

Showing results (101-110 of 187) with videos related to

Sort By:
Pageof 19
Thrombosis and Haemostasis|December 5, 2014
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trialJames D Douketis, Jeff S Healey, Martina Brueckmann, et al.
Circulation|July 31, 2015
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and OutcomesWobo Bekwelem, Stuart J Connolly, Jonathan L Halperin, et al.
Thrombosis Research|February 27, 2016
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trialJames D Douketis, Jeff S Healey, Martina Brueckmann, et al.
Circulation|January 5, 2011
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversionRangadham Nagarakanti, Michael D Ezekowitz, Jonas Oldgren, et al.
Journal of the American Heart Association|January 18, 2019
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY TrialZiad Hijazi, Paolo Verdecchia, Jonas Oldgren, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Lancet (London, England)|August 31, 2010
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLars Wallentin, Salim Yusuf, Michael D Ezekowitz, et al.
Journal of the American Heart Association|December 9, 2020
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial FibrillationZiad Hijazi, Lars Wallentin, Johan Lindbäck, et al.
Cardiovascular Research|August 6, 2021
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillationTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Pageof 19